To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

THLD $2.99 1.70 +56.9%
BPAX $0.74 0.06 +8.1%
INFI $6.95 0.49 +7.1%
YMI $2.33 0.16 +6.9%
SNSS $1.51 0.10 +6.6%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CLDX $4.98 -0.48 -9.6%
RNN $0.60 -0.03 -5%
INO $0.68 -0.02 -2.9%
NWBO.OB $0.36 -0.01 -2.8%
IMUC.OB $1.61 -0.04 -2.5%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.





Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

Cancer Research Organization Broadcasts Healthy Eating Tips with Top Chefs around the Country

(Yahoo! Finance) Feb 3, 2012 - After she was diagnosed with breast cancer when she was three weeks pregnant, Lynette Bisconti, president of The Gateway for Cancer ResearchSM www.demandcurestoday.org, began an aggressive personal campaign to beat the deadly disease. While she took advantage of traditional cancer treatments, she also battled cancer from a holistic perspective, learning how to support her well-being emotionally, mentally and physically.
read article 



Health Discovery Corporation Launches Android Version of Popular MelApp, Melanoma Risk Analysis Mobile Phone App

(Healthcare IT News) Feb 1, 2012 - Health-conscious consumers can easily learn about melanoma and identify areas on their skin which may need attention from a specialist, anytime, anywhere with their iPhone, iPod Touch and iPad, as well as Android smartphone.
read article 



Merck Wins Approval For Extended Release Janumet

(NJ.com/Associated Press) Feb 2, 2012 - Drugmaker Merck & Co Inc. said Thursday it received U.S. approval for an extended-release version of its diabetes drug Janumet designed to be taken once a day, instead of twice a day.
read article 



Sucampo Gains as Bowel Drug Shows Effectiveness in Study: Washington Mover

(Bloomberg) Feb 3, 2012 - Sucampo Pharmaceuticals Inc. surged as much as 46 percent over two days after reporting that its experimental medicine for opioid-induced bowel dysfunction met goals in a late-stage clinical trial.
read article 



Alzheimer's Disease "Jumps" Across Brain Cells to Spread

(CBS News) Feb 2, 2012 - Alzheimer's disease spreads through the brain by jumping from one cell to another, according to a new study.
read article 



Administration Touts $2.1 Billion in Prescription Drug Savings For Medicare Recipients

(The Hill/Healthwatch blog) Feb 2, 2012 - Some 3.6 million people Medicare recipients saved a total of $2.1 billion on their prescription drugs in 2011 thanks to the healthcare reform law, the Obama administration announced Thursday.
read article 



Oncology Care Leaders Gather in Baltimore for Association of Community Cancer Centers 38th Annual National Meeting

(ACCC) Feb 2, 2012 - Leaders from the nation’s hospital-based cancer programs and oncology practices will gather in Baltimore, Maryland, for the Association of Community Cancer Centers’ (ACCC) 38th Annual National Meeting.
read press release 



Dayton Physicians Network and Zangmeister Center Join RainTree Oncology Services Network

(RainTree Oncology Services) Feb, 2012 — RainTree Oncology Services today announced that Dayton Physicians Network and The Zangmeister Center, based in Columbus, Ohio, leaders in technically advanced, high quality community-based medical and cancer care, have joined the RainTree Oncology membership to obtain access to advanced oral oncologic drug acquisition and management services.
read corporate press release 



Optimal Antiemetic Control Requires Optimal Treatment

(GU Cancers Symposium Daily News/ASCO) Feb 2, 2012 - The November 1, 2011 issue of the Journal of Clinical Oncology (JCO) featured a guideline update to “The American Society of Clinical Oncology Clinical Practice Guideline Update on Antiemetics in Oncology,” which was originally published in 1999 and updated once in 2006. It is the most frequently downloaded guideline from among the ASCO guidelines repertoire.
read article 



ASCO Committee Works to Improve Survivor Care

(GU Cancers Symposium Daily News/ASCO) Feb 2, 2012 - Twelve million people in the United States are a living testament to the compassionate care of their physicians and nurses and to the astonishing advances in oncology research—they are cancer survivors. It is the wish of every oncology care provider to see this number continue to increase.
read article 



Medicare Physician Payment Reform in 2011 and What to Expect in 2012

(ASTRO) Feb 2, 2012 - Congressional lawmakers touted 2011 as the year they would finally figure out a new way to reimburse Medicare physicians and do away with the repeated short-term "fixes" to the sustainable growth rate (SGR) formula.
read article 



Cooperative Group Revitalization Efforts Ongoing

(GU Cancers Symposium Daily News/ASCO) Feb 2, 2012 - In November 2011, the National Cancer Institute (NCI) Board of Scientific Advisors unanimously approved a proposal to transform the Cooperative Group Program into a National Clinical Trials Network (NCTN)—including a recommended $25.6 million increase in funding.
read article 



From Vision to Reality: Implementing ASCO’s Clinical Trials Strategic Plan

(GU Cancers Symposium Daily News/ASCO) Feb 2, 2012 - An interview with Cancer Research Committee Past Chair Neal J. Meropol, MD.
read article 



Dr. Mark A. Rubin to Provide Insights From Genomic Approaches to Oncology Discovery

(GU Cancers Symposium Daily News/ASCO) Feb 2, 2012 - Dr. Rubin is among the country’s foremost board-certified, academic anatomic pathologists and has received wide recognition for advancing the field of biomarkers in prostate cancer.
read article 



Threshold Jumps on Merck KGaA Cancer-Drug Partnership: San Francisco Mover

(Bloomberg) Feb 3, 2012 - Threshold Pharmaceuticals Inc. surged the most in a year after German drugmaker Merck KGaA agreed to pay as much as $525 million for the right to jointly develop and sell a drug for cancer.
read article 



Geron Completes Enrollment in Phase 2 Clinical Trial of Imetelstat in Breast Cancer

(Reuters) Feb 2, 2012 - Geron Corporation today announced that the company has completed enrollment in the randomized Phase 2 clinical trial of imetelstat, in combination with paclitaxel, in patients with locally recurrent or metastatic breast cancer (MBC).
read article 



Soy Isoflavone Supplements Did Not Provide Breast Cancer Protections

(AACR) Feb 3, 2012 - Soy isoflavone supplements did not decrease breast cancer cell proliferation in a randomized clinical trial, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.
read press release 



Study of the Day: Gene Mutations Found in Kids With Brain Cancer

(The Atlantic) Feb 3, 2012 - Just in time for World Cancer Day tomorrow: New research uncovers the genetic roots of pediatric tumors and suggests new treatment paths.
read article 



New Research Confirms Need For Lung Cancer Testing

(UC Denver) Feb 2, 2012 - Different kinds of lung cancer behave in different ways, suggesting they are fundamentally different diseases.
read press release 



Queensland Researchers Make Cancer Treatment Breakthrough

(QIMR [Australia]) Feb 1, 2012 - The culmination of 10 years of collaborative research between scientists from the Queensland Institute of Medical Research (QIMR) and The University of Hong Kong (HKU) Li Ka Shing Faculty of Medicine has led to a significant breakthrough in the treatment of nasopharyngeal carcinoma (NPC), an aggressive throat cancer with a high prevalence in South-East Asia.
read press release 



Genomic Health Presents Results Furthering Understanding of Biology of Prostate Cancer at the 2012 Genitourinary Cancers Symposium

(Reuters) Feb 3, 2012 - Genomic Health, Inc. today announced results from a large clinical study in prostate cancer evaluating the relationship of microRNAs, a novel class of biomarkers, to clinical outcomes for patients with early-stage prostate cancer.
read article 



Aeterna Zentaris Reports Updated Phase 1 Trial Results For AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer at ASCO GCS Meeting

(Yahoo! FInance) Feb 3, 2012 - Aeterna Zentaris Inc. today reported positive updated results for the Phase 1 portion of its ongoing Phase 1/2 study in castration- and taxane-resistantprostate cancer (CRPC) with AEZS-108 (zoptarelin doxorubicin),the Company's targeted cytotoxic luteinizing hormone-releasing hormone (LHRH) analog.
read article 



Cabozantinib Shows Encouraging Activity in Heavily Pretreated Patients With Advanced Renal Cell Carcinoma

(MarketWatch) Feb 3, 2012 - Exelixis, Inc.today reported preliminary data from a cohort of heavily pretreated patients with metastatic refractory renal cell carcinoma (RCC) participating in an ongoing phase 1b trial of cabozantinib.
read article 



Denosumab Benefits Greatest in Men With Rapid PSA Kinetics

(GU Cancers Symposium Daily News/ASCO) Feb 3, 2012 - The large, international, phase III 147 Trial previously established denosumab as the only therapy to prolong bone metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) at high risk for the spread of disease to bone.
read article 



Talon Therapeutics' Product Candidate Marqibo(R) to be Assessed by Oncologic Drug Advisory Committee (ODAC) on March 21, 2012 With a PDUFA Date of May 13, 2012

(Yahoo! Finance) Feb 3, 2012 - Talon Therapeutics Inc. announced Marqibo(R) (vincristine sulfate liposomes injection) is scheduled to be assessed by ODAC on Wednesday, March 21, 2012.
read article